Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
b decrease » _ decrease (Expand Search), b1 decreased (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
16 b » 16 _ (Expand Search), 1 b (Expand Search), 6 b (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
b decrease » _ decrease (Expand Search), b1 decreased (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
16 b » 16 _ (Expand Search), 1 b (Expand Search), 6 b (Expand Search)
-
141
-
142
-
143
-
144
Patients with NDO have decreased BKα subunit mRNA expression in DSM.
Published 2013“…<p>qPCR analyses showing 15.8-fold, 1.1-fold, and 1.6-fold decreases in BKα (<b>A</b>), BKβ1 (<b>B</b>), and BKβ4 subunits (<b>C</b>) mRNA expression in NDO DSM tissue (n = 3, N = 3) compared to controls (n = 7, N = 7; **P<0.01). …”
-
145
-
146
-
147
WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression.
Published 2024“…<b>C.</b> RT-qPCR of WT1, p<0.05(*), vFLIP(ns), LANA, p<0.0001(****), K8.1, p<0.0001(****), and BCL2 p<0.05(*) in the setting of WT1 knockdown in ISLK BAC-16 with WT1 siRNA in comparison to a control siRNA using two-sided, unpaired student’s t-tests. …”
-
148
Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines.
Published 2013“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”
-
149
-
150
-
151
-
152
-
153
Fold decrease in virulence gene expression of <i>Salmonella in vivo</i> and <i>in vitro</i><sup>a</sup>.
Published 2014“…Values represent down-regulation (fold-decrease) of gene expression.</p>#<p>Value for each gene represents a significant difference (<i>P</i><0.05) between the treatment and control samples in the <i>in vitro</i> experiment. …”
-
154
A homozygous point mutation in the <i>Mrps34</i> gene causes a decrease in the MRPS34 protein.
Published 2015“…The 5′- and 3′-untranslated regions are shown as grey boxes and the predicted mitochondrial targeting sequence is shown as a black box (predicted using MitoProtII, [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1005089#pgen.1005089.ref040" target="_blank">40</a>]). …”
-
155
-
156
-
157
-
158
-
159
-
160